title: Bovine glycomacropeptide is anti-inflammatory in rats with hapten-induced colitis.
abstract: Milk kappa-casein-derived glycomacropeptide has immunomodulatory and bacterial toxin binding effects. The intestinal anti-inflammatory activity of glycomacropeptide was assessed in trinitrobenzenesulfonic acid-induced colitis in rats. Rats were administered glycomacropeptide daily starting either 2 d before (pretreatment) or 3 h after (post-treatment) colitis induction. Pretreatment with glycomacropeptide had a dose-dependent anti-inflammatory effect, characterized by lower body weight loss, decreased anorexia (57%), colonic damage (65%), and weight to length ratio (32%), as well as a reduction in colonic alkaline phosphatase activity (42%) and interleukin 1, trefoil factor 3, and inducible nitric oxide synthase mRNA levels (P < 0.05). The mechanism of action of glycomacropeptide is unknown but is consistent with an inhibition of the activation of immune cells. The magnitude of the anti-inflammatory effect was generally comparable to that of sulfasalazine, an established drug used in the treatment of inflammatory bowel disease. Bovine glycomacropeptide may play a role in the management of patients with inflammatory bowel disease.
authors.affiliation: Department of Biochemistry and Molecular Biology, School of Pharmacy, University of Granada, Spain.
authors.forename: Abdelali
authors.initials: A
authors.lastname: Daddaoua
authors.forename: Víctor
authors.initials: V
authors.lastname: Puerta
authors.forename: Antonio
authors.initials: A
authors.lastname: Zarzuelo
authors.forename: María D
authors.initials: MD
authors.lastname: Suárez
authors.forename: Fermín
authors.initials: F
authors.lastname: Sánchez de Medina
authors.forename: Olga
authors.initials: O
authors.lastname: Martínez-Augustin
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001483:Base Sequence; D002417:Cattle; D003092:Colitis / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D003106:Colon / Q000187:drug effects / Q000473:pathology; D017931:DNA Primers; D005786:Gene Expression Regulation / Q000187:drug effects; D006020:Glycopeptides / Q000627:therapeutic use*; D006241:Haptens; D007375:Interleukin-1 / Q000235:genetics; D009336:Necrosis; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats; D014302:Trinitrobenzenesulfonic Acid
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D017931:DNA Primers; D006020:Glycopeptides; D006241:Haptens; D007375:Interleukin-1; D012333:RNA, Messenger; D014302:Trinitrobenzenesulfonic Acid